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Abstract
Background: Lipid-soluble thiamine precursors have a much higher bioavailability than genuine thiamine
and therefore are more suitable for therapeutic purposes. Benfotiamine (S-benzoylthiamine O-
monophosphate), an amphiphilic S-acyl thiamine derivative, prevents the progression of diabetic
complications, probably by increasing tissue levels of thiamine diphosphate and so enhancing transketolase
activity. As the brain is particularly sensitive to thiamine deficiency, we wanted to test whether intracellular
thiamine and thiamine phosphate levels are increased in the brain after oral benfotiamine administration.
Results: Benfotiamine that is practically insoluble in water, organic solvents or oil was solubilized in 200
mM hydroxypropyl-β-cyclodextrin and the mice received a single oral administration of 100 mg/kg.
Though thiamine levels rapidly increased in blood and liver to reach a maximum after one or two hours,
no significant increase was observed in the brain. When mice received a daily oral administration of
benfotiamine for 14 days, thiamine derivatives were increased significantly in the liver but not in the brain,
compared to control mice. In addition, incubation of cultured neuroblastoma cells with 10 μM
benfotiamine did not lead to increased intracellular thiamine levels. Moreover, in thiamine-depleted
neuroblastoma cells, intracellular thiamine contents increased more rapidly after addition of thiamine to
the culture medium than after addition of benfotiamine for which a lag period was observed.
Conclusion: Our results show that, though benfotiamine strongly increases thiamine levels in blood and
liver, it has no significant effect in the brain. This would explain why beneficial effects of benfotiamine have
only been observed in peripheral tissues, while sulbutiamine, a lipid-soluble thiamine disulfide derivative,
that increases thiamine derivatives in the brain as well as in cultured cells, acts as a central nervous system
drug. We propose that benfotiamine only penetrates the cells after dephosphorylation by intestinal alkaline
phosphatases. It then enters the bloodstream as S-benzoylthiamine that is converted to thiamine in
erythrocytes and in the liver. Benfotiamine, an S-acyl derivative practically insoluble in organic solvents,
should therefore be differentiated from truly lipid-soluble thiamine disulfide derivatives (allithiamine and
the synthetic sulbutiamine and fursultiamine) with a different mechanism of absorption and different
pharmacological properties.
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It is well known that thiamine deficiency results in neuro-
logical disorders such as beriberi or Wernicke-Korsakoff
syndrome [1]. It is generally assumed that the symptoms
arise from decreased activity of thiamine diphosphate
(ThDP) – dependent enzymes such as transketolase and
pyruvate and oxoglutarate dehydrogenases, with subse-
quent impairment of carbohydrate metabolism in the
brain. It is not known to what extent, if any, the decrease
in other thiamine derivatives such as thiamine triphos-
phate (ThTP, [2]) and the newly discovered adenosine thi-
amine triphosphate (AThTP, [3]) are involved in the
appearance of these symptoms.
In a number of diseases, beneficial effects of the adminis-
tration of free, unphosphorylated thiamine have been
reported. Thus, high-dose thiamine therapy reversed the
symptoms of Wernicke's encephalopathy [1] and pre-
vented incipient diabetic nephropathy [4] and diabetic
dyslipidaemia [5] in experimental diabetes in the rat.
Other reports suggested that thiamine may protect against
free-radical mediated neurotoxicity [6] and that it may
have a cytoprotective effect on cultured neonatal rat cardi-
omyocytes under hypoxic insult [7]. These protective
effects may be due to increased tissue ThDP levels after
thiamine treatment, but effects mediated by other phos-
phorylated thiamine derivatives such as ThTP and AThTP
cannot be ruled out.
It is known that free thiamine is transported across plasma
membranes by high affinity carriers [8], but the rate of
transport is generally slow. For that reason, a variety of
lipophilic thiamine derivatives have been synthesized.
These compounds can easily diffuse through plasma
membranes thus bypassing the rate-limiting transport sys-
tem required for free thiamine. Once incorporated into
the cells, these lipophilic derivatives can be rapidly con-
verted to thiamine through enzymatic or non-enzymatic
processes. The first lipophilic thiamine derivative was iso-
lated from garlic (Allium sativum) extracts in the early
1950s [9]. It is an allyl disulfide derivative called allithia-
mine (Fig. 1). Since then, several analogs of this molecule
were synthesized with the hope that they would be better
absorbed and have a higher bioavailability than thiamine
hydrochloride or mononitrate [10,11]. These lipophilic
disulfides are often referred to as "allithiamines", in our
opinion an improper denomination as they are synthetic
molecules not present in Allium species and do not pos-
sess any allyl group.
Presently, two lipophilic disulfide derivatives are used as
therapeutic agents: thiamine tetrahydrofurfuryl disulfide
("fursultiamine", Fig. 1) [12] and O-isobutyrylthiamine
disulfide ("sulbutiamine", Fig. 1) [13]. Sulbutiamine
turned out to be a psychotropic drug prescribed for the
symptomatic treatment of functional asthenias [13]. It
was found that chronic treatment with sulbutiamine (52
mg/kg, i.p.) increases thiamine, ThMP, ThDP and ThTP
levels in the rat brain as well as in peripheral tissues [14].
Concerning fursultiamine, it is not clear whether it has
specific effects on brain function [12] but it exerts a posi-
tive inotropic effect in heart muscle [15-17].
S-benzoylthiamine O-monophosphate ("benfotiamine",
Fig. 1) is a third derivative with better bioavailability than
thiamine. In contrast to the above-mentioned derivatives
it is not a disulfide but an S-acyl derivative. It prevents the
development and the progression of diabetic complica-
tions [18-23]. It was suggested that treatment with benfo-
tiamine blocks three major pathways (the hexosamine
pathway, the advanced glycation end product formation
pathway and the diacylglycerol-protein kinase pathway)
of hyperglycemic damage, probably by removal of glycer-
aldehyde 3-phosphate and fructose 6-phosphate through
activation of the pentose phosphate enzyme transketolase
[18]. Other beneficial effects of benfotiamine were the
reduction of glucose toxicity [19,20], alleviation of diabe-
tes-induced cerebral oxidative damage [21], acceleration
of the healing of ischemic diabetic limbs in mice [22] and
rescue of cardiomyocyte contractile dysfunction in exper-
imental diabetes mellitus [23].
Whilst different studies show that administration of ben-
fotiamine leads to higher thiamine blood levels than
administration of water-soluble thiamine [10,24-27],
practically no information is available concerning its
effects on the brain. The aim of the present study was to
check whether oral administration of benfotiamine
increases the levels of thiamine and its phosphorylated
derivatives in the brain of mice.
Results
Acute experiment
As previous studies do not mention the use of a specific
carrier for the gavage of mice with benfotiamine [18,23],
we first suspended benfotiamine in water and adminis-
tered it by force-feeding (100 μl containing a dose equal
to 100 mg of benfotiamine per kg), using a syringe with a
tube that was inserted into the stomach. We sacrificed the
animals after 1 hour and we determined thiamine deriva-
tives in the blood. Thiamine levels proved to be highly
variable: in some animals thiamine levels were up to 10
times higher than in the controls, while in others they
were hardly increased. Benfotiamine is very sparingly sol-
uble in water (at least at pH < 8.0) and it is possible that
in some cases, either most of the material remained
attached to the syringe or the force-feeding tube or it was
eliminated with the bolus. Therefore, we tested different
hydrophobic solvents such as oil (Mineral oil, Sigma
M5904) and organic solvents (ethanol, octanol, dimethylPage 2 of 11
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Structures of the S-acyl derivative benfotiamine and the disulfide compounds allithiamine, fursultiamine and sulbutiamineFigure 1
Structures of the S-acyl derivative benfotiamine and the disulfide compounds allithiamine, fursultiamine and 
sulbutiamine. The thioester bond in benfotiamine is indicated in blue, while the disulfide bond in allithiamine, fursultiamine 
and sulbutiamine is drawn in red. The allyl group in allithiamine is indicated in green.
BMC Pharmacology 2008, 8:10 http://www.biomedcentral.com/1471-2210/8/10sulfoxide), but no significant solubility was observed.
Finally, we obtained a homogenous solution of benfo-
tiamine by forming inclusion complexes in a 200 mM
hydroxypropyl-β-cyclodextrin (HP-β-CD) solution that
was used for force-feeding. This time, the inter-animal var-
iability was reasonable (25%, S.E.M/mean × 100, n = 12)
and we found that, one hour after the administration, thi-
amine, ThMP and ThDP levels in the blood were increased
by a factor of respectively 822, 14 and 4.7 (Fig. 2). Highly
significant increases of free thiamine and ThMP were also
observed in the liver, but not in the brain.
Pharmacokinetics
First, we measured tissue levels of thiamine, ThMP and
ThDP for up to 6 hours after a single oral administration
of benfotiamine (100 mg/kg in a HP-β-CD solution). In
the blood, thiamine levels rapidly increased, reaching a
maximum after 120 min and slowly decreasing thereafter
(Fig. 3). ThDP levels steadily increased before reaching a
maximum after 4 hours. For ThMP, the highest level was
already reached after 30 min and it slowly decreased dur-
ing the next hours. In the liver, all derivatives peaked after
1 hour before decreasing to near normal levels after 2
hours. No significant variations were observed in the
brain. Total thiamine content (per mg of protein) was
about twice higher in the liver than in the brain before
benfotiamine administration. One hour after the admin-
istration, the ratio was over 10. However, liver thiamine
decreased rather fast after 1 – 2 hours. In most samples, we
also observed the presence of ThTP and AThTP, but the
levels of these compounds in the liver and the brain were
not influenced by the treatment (not shown).
Chronic experiment
As no increase in brain thiamine levels was observed after
a single administration of benfotiamine, we decided to
test a longer treatment. The animals received a daily oral
administration of either 100 μl of a solution of benfo-
tiamine (100 mg/kg) in 200 mM HP-β-CD or 100 μl of a
200 mM HP-β-CD solution for 14 days and were sacri-
ficed 24 hours later. After treatment with benfotiamine,
the levels of free thiamine, ThMP and ThDP were
increased in the liver but not in the brain (Fig. 4). Again,
the small amounts of ThTP and AThTP found did not
depend on the conditions of treatment.
Cell culture experiments
As treatment with benfotiamine did not yield elevated
brain thiamine levels, we wanted to test whether this mol-
ecule is able to easily cross cell membranes in cultured
cells. We chose mouse neuroblastoma cells (Neuro 2a) as
we have previously characterized these cells with respect
to thiamine transport [8,28], metabolism [29] and defi-
ciency [30]. The thiamine concentration in the commer-
cial Dulbecco's modified Eagle's medium (DMEM) is 10
μM [8]. Therefore, once the cells were nearly confluent,
DMEM was replaced by a saline containing 10 μM of
either thiamine or benfotiamine. After incubation for up
to 4 h at 37°C, the thiamine content of the cells was deter-
mined. We did not observe any increase in intracellular
thiamine after incubation with benfotiamine and there
were no significant differences between the thiamine and
benfotiamine groups (Fig. 5). This is in sharp contrast
with previous experiments where incubation of the same
cell line with 10 μM sulbutiamine under the same condi-
tions led to a 10-fold increase in intracellular free
(unphosphorylated) thiamine within 2 hours [29].
As mentioned above, the thiamine concentration in most
commercial culture media is about 10 μM, one or two
orders of magnitude higher than the Km for the high affin-
ity thiamine transport present in most cells [8,28,29].
Cells grown under those conditions are thus saturated
with thiamine. Therefore, we wanted to test whether ben-
fotiamine had any effect on intracellular thiamine levels
in Neuro 2a cells previously thiamine-depleted. The cells
were grown for 8 days in a medium containing about 7
nM thiamine. Then either benfotiamine (1 μM) or thia-
mine (1 μM) was added (Fig. 6). After 2 hours in the pres-
ence of thiamine, intracellular thiamine already reached a
maximum, while with benfotiamine an important lag
period was observed. This experiment confirms that thia-
mine enters Neuro 2a cells more rapidly than benfo-
tiamine. The lag period can be explained if benfotiamine
is first dephosphorylated by ecto-phosphatases to the lip-
idsoluble S-benzoylthiamine that can then enter the cells
(see below).
Discussion
Mechanism of action of benfotiamine
In 1961, Wada et al. reported the physicochemical prop-
erties of benfotiamine and its possible use as a therapeutic
agent [31]. Benfotiamine is more easily absorbed by the
body and oral administration results in higher thiamine
and ThDP blood levels in animals than an equivalent
dose of thiamine. A few years, later Shindo and coworkers
[32-35] studied in more detail the mechanism of absorp-
tion and the metabolic fate of benfotiamine in animal tis-
sues. Their results suggested that benfotiamine (given
orally) is first dephosphorylated to S-benzoylthiamine by
the ecto-alkaline phosphatase present in the brush bor-
ders of intestinal mucosal cells. The more lipophilic S-
benzoylthiamine then diffuses through the membranes of
intestinal and endothelial cells and appears in the venous
mesenteric blood. A significant part of S-benzoylthiamine
is captured by erythrocytes [34] and converted to free thi-
amine through a slow non-enzymatic transfer of the S-
benzoyl group to SH groups of glutathione. In the liver,
the remainder can be enzymatically hydrolyzed to thia-
mine and benzoic acid by thioesterases present in thePage 4 of 11
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Contents of thiamine, ThMP, ThDP and total thiamine in the blood, the liver and the brain of mice (strain sv129) 1 hour after a single oral administration of 100 μl of 200 mM HP-b-CD or benf tiamine (100 mg/kg) in approximately 100 μl of a 200 mM HP-b-CD solutionFigure 2
Contents of thiamine, ThMP, ThDP and total thiamine in the blood, the liver and the brain of mice (strain 
sv129) 1 hour after a single oral administration of 100 μl of 200 mM HP-b-CD or benfotiamine (100 mg/kg) in 
approximately 100 μl of a 200 mM HP-b-CD solution. The data were analyzed by MANOVA (Wilk's Lambda, p = 
0.0002, 0.0145 and 0.27 for blood, liver and brain respectively) followed by ANOVA for each thiamine compound (*, p < 0.05; 
**, p < 0.01). The results are expressed as mean ± SEM for 4 animals in each group.
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Time-dependent tissue content of thiamine derivatives after a single oral administration of benfotiamine (100 mg/kg) in approx-imat ly 100 μl of a 200 mM HP-β-CD solution n mice (s rain C57B6)F gure 3
Time-dependent tissue content of thiamine derivatives after a single oral administration of benfotiamine (100 
mg/kg) in approximately 100 μl of a 200 mM HP-β-CD solution in mice (strain C57B6). The results are expressed 
as mean ± SEM for 6 – 7 animals for each time point.
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atives require a reduction either enzymatically in the liver
by glutathione or non enzymatically in blood by glutath-
ione and possibly other substrates [36]. In the present
work, we show that after oral administration of benfo-
tiamine to mice, free thiamine appears in the liver at a fast
rate, reaching a maximum after one hour, while in the
blood the maximum is reached only after two hours (Fig.
3). We therefore propose that most of the S-benzoylthia-
mine present in the mesenteric blood is captured by the
liver and transformed into thiamine. The excess thiamine
formed is then rapidly released into the blood stream, as
shown by the fast decrease of thiamine content in the liver
after 1 – 2 hours (Fig. 3). Such a scheme is in agreement
with an earlier report that, after infusion of benfotiamine
to the small intestine of the dog, mainly free thiamine
(not S-benzoylthiamine) was detected in the carotid
blood [35]. Free thiamine is not lipophilic and cannot
cross the blood-brain barrier by simple diffusion. Trans-
port of blood thiamine to the brain parenchyma is carrier-
mediated and it is a slow process [37]. In the present
study, we find that blood thiamine concentration in the
control animals is approximately 0.4 μmol/l, a value close
to the half-maximal activation constant for the high affin-
ity transport of thiamine across the blood-brain barrier
[8]. Though a second, low affinity, component of thia-
mine transport was also observed, its contribution was
small. Thus, raising free blood thiamine concentrations
does not necessarily lead to an important increase in thia-
mine transport across the blood-brain barrier. It is there-
fore not very surprising that benfotiamine administration
does not lead to an increase in total thiamine content of
the brain (Figs 2, 3 and 4). It should be noted however
that one study showed a 90% increase of ThDP levels in
the brains of rats that received a dose of 1645 mg of ben-
fotiamine/kg of diet for 6 months [27].
Differences between benfotiamine and lipophilic thiamine 
disulfide derivatives
Wada et al. already noted that benfotiamine was sparingly
soluble in organic solvents such as benzene, chloroform
and methanol, but was readily soluble in aqueous media
at pH ≥ 8.0 [31]. This is not surprising as the phosphoryl
group of benfotiamine has two negative charges at alka-
line pH. Here, we confirm that benfotiamine is sparingly
soluble in water at pH ≤ 7.0 and cannot be dissolved in
octanol or oils. Thus benfotiamine should not be classi-
fied as a "lipophilic" compound as many authors still do
[10,24,25,38]. Indeed, benfotiamine appears unable to
diffuse across cell membranes. We have shown here that
intracellular thiamine content is not increased in cultured
neuroblastoma incubated in the presence of 10 μM ben-
fotiamine, while it was increased ten-fold after incubation
with 10 μM sulbutiamine [29]. Moreover, after a chronic
treatment of rats with sulbutiamine intracellular thiamine
derivatives were increased by respectively 250% (thia-
mine), 40% (ThMP), 25% (ThDP) and 40% (ThTP) [14].
This is in apparent contradiction with results obtained
with cultured cells of endothelial origin [18-20,39], show-
ing that benfotiamine is able to counteract glucose toxic-
ity in these cells by increasing transketolase activity.
However, the benfotiamine concentrations used were 50
– 100 μM, much higher than in our study. Hammes et al.
even report that there was no effect on transketolase activ-
ity in cultured endothelial cells at 10 or 25 μM [18]. In any
event, this is no proof that benfotiamine is able to cross
the membranes: indeed, cultured endothelial cells seem
to possess an ecto-alkaline phosphatase [40]. It is there-
Contents of thiamine, ThMP, ThDP and total thiamine in the liver a d the br in of mice (strain sv129) after d ily oral adminis ration of 200 M HP-β-CD (8 animals) or b nfo-tia e (100 mg/kg) in approximately 100 μl of a 200 HP β-D soluti n (10 animals) for 14 daysFigur 4
Contents of thiamine, ThMP, ThDP and total thia-
mine in the liver and the brain of mice (strain sv129) 
after daily oral administration of 200 mM HP-β-CD (8 
animals) or benfotiamine (100 mg/kg) in approxi-
mately 100 μl of a 200 HP-β-CD solution (10 animals) 
for 14 days. The data (mean ± SEM) were analyzed by 
MANOVA (Liver : Wilk's Lambda = 0.24, p = 0.0061; Brain : 
Wilk's Lambda = 0.779, p = 0.48) followed by an ANOVA for 
each thiamine compound (*, p < 0.05; **, p < 0.01).Page 7 of 11
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least partially dephosphorylated to S-benzoylthiamine
that can enter the cells as in the case of the intestinal
mucosa. The slow dephosphorylation to S-benzoylthia-
mine might also explain the lag period observed between
the addition of benfotiamine to thiamine-depleted Neuro
2a cells and the increase in intracellular thiamine deriva-
tives (Fig. 6). In erythrocytes, it was shown that fur-
sultiamine, a lipophilic disulfide, is rapidly incorporated
into the cells while benfotiamine is not [41]. Taken
together, these results strongly suggest that benfotiamine
is unable to cross plasma membranes unless it is dephos-
phorylated.
Benfotiamine and sulbutiamine have different 
pharmacological profiles
Since the discovery of allithiamine [9], a number of deriv-
atives were synthesized. These showed higher bioavaila-
bility than thiamine hydrochloride or mononitrate. Lipid-
soluble thiamine derivatives were developed mainly in
Japan for the treatment of beriberi. It was therefore sur-
prising that sulbutiamine appeared to exert specific effects
on brain function. Indeed, it seems to improve memory in
rodents [42,43] and, in humans, it seems to be beneficial
against functional asthenias [13,44,45]. These effects have
not been reported with thiamine. This difference might be
explained if we assume that sulbutiamine (or its degrada-
tion product thiamine disulfide) can cross the blood-
brain barrier and have specific actions in neurons. How-
ever, there is so far no direct evidence that untransformed
sulbutiamine is indeed found in the brain. Concerning
benfotiamine, there is no evidence that it has any specific
effect on the central nervous system, but during the last
few years, there was considerable interest in the therapeu-
tic potential of benfotiamine in peripheral tissues. Indeed,
it was found effective for the protection of diabetic com-
plications such as diabetic neuropathy [18-23] and alco-
holic neuropathy [46]. Our results are in agreement with
the different pharmacological profiles of sulbutiamine
and benfotiamine. We previously found that sulbu-
tiamine treatment significantly increases thiamine, ThMP,
ThDP and ThTP content of rat brain [14], while the
present results show that benfotiamine, at a twice higher
dose, is unable to raise the levels of intracerebral thiamine
phosphate derivatives (Figs 2, 3 and 4). This is in agree-
ment with a previous study showing that after administra-
tion of 3H-benfotiamine, liver and kidney were labeled to
a higher degree than brain and muscles [47], but this
study did not make a difference between benfotiamine
and its labeled metabolites and degradation products.
Furthermore our results on cultured neuroblastoma cells
show that benfotiamine, in contrast to sulbutiamine, does
not easily cross cell membranes (Figs 5 and 6). It would
therefore be interesting to test whether a thiamine
disulfide compound such as sulbutiamine or fur-
sultiamine, would not be more efficient and act at lower
concentrations than benfotiamine in counteracting dia-
betic complications. A recent study has shown that, at
high concentration (300 μM), benfotiamine exerts a direct
antioxidant effects in three different kidney cell lines,
Effect of thiamine and benfotiamine on the total thiamine content in thiamine- epleted Neuro 2a c llsFigure 6
Effect of thiamine and benfotiamine on the total thia-
mine content in thiamine-depleted Neuro 2a cells. 
The cells were grown for 8 days in thiamine deficient DMEM 
medium containing 5% fetal calf serum, before addition of thi-
amine (1 μM, m) or benfotiamine (1 μM, l) and intracellular 
thiamine derivatives were determined at the times indicated. 
The data (mean ± SEM, n = 3) were analyzed by two-way 
ANOVA followed by the Bonferroni post-test for compari-
son of the benfotiamine and the thiamine groups at different 
times (*, p < 0.05).
Contents of total (m, l) and unphosphorylated ( , n) thia-mine during incubation of Neuro2a cells in th  prese ce of 10 μM thiami e (m, ) or b nf ti mine (l, n)Figure 5
Contents of total (m, l) and unphosphorylated (h, 
n) thiamine during incubation of Neuro2a cells in the 
presence of 10 μM thiamine (m, h) or benfotiamine 
(l, n). The data are expressed as mean ± SEM for 4 experi-
ments.Page 8 of 11
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increased transketolase activity [48]. It is however not yet
clear to what extend, if any, this may be involved in the
improvement of diabetic complications.
Conclusion
Our results show that oral administration of benfo-
tiamine leads to significant increases in thiamine, ThMP
and ThDP levels in blood, liver but not in the brain. This
difference is in agreement with the known pharmacologi-
cal profile of benfotiamine, i.e. the beneficial effects of the
drug concern peripheral tissues but not the central nerv-
ous system. Like disulfide derivatives, benfotiamine may
be useful for the treatment of acute peripheral syndromes
of thiamine deficiency because it is better absorbed than
thiamine, but in contrast to sulbutiamine, it seems to be
devoid of specific effects on brain function. On the other
hand, sulbutiamine should be much more efficient than
benfotiamine in the treatment of Wernicke-Korsakoff syn-
drome. Physico-chemical data as well as studies with iso-
lated cells strongly suggest that, in contrast to disulfide
derivatives, benfotiamine is not a lipophilic compound
and is unable to diffuse through cell membranes unless it
is first dephosphorylated by ecto-alkaline phosphatases.
Finally, it seems important to us that, because of different
chemical, metabolic and pharmacological properties, a
clear distinction should be made between lipophilic thia-
mine disulfides (derived from allithiamine) and S-acyl
derivatives such as benfotiamine.
Methods
Administration of benfotiamine
Benfotiamine (Sigma-Aldrich) was dissolved in a 200 mM
solution of hydroxypropyl-β-cyclodextrin (HP-β-CD,
Roquette, Lestrem, France) at a concentration of 25 mg/
ml. The solution was homogenized at 4°C. The mice were
force-fed with a dose of 100 mg benfotiamine/kg in
approximately 100 μl using a syringe prolonged by a flex-
ible tube that was inserted into the stomach. The mice
strains (male, 8 weeks old) were either C57B6 or Sv129.
Control animals received an oral administration of 100 μl
HP-β-CD solution (200 mM) without benfotiamine. The
local committee for animal care and use approved all ani-
mal experiments.
Sample preparation and determination of thiamine 
derivatives by HPLC
The mice were anesthetized with isoflurane and the fore-
brain and the liver were collected. For collecting blood
samples, the animals were anesthetized with isoflurane
and heparin sulfate sodium salt (5000 I.U./ml, Leo
Pharma, Wilrijk, Belgium) was injected directly into the
heart (50 μl). Tissues were stored at -80°C until sample
preparation. About 50 mg of tissue were homogenized in
500 μl trichloroacetic acid (TCA, 12% w/v) in a glass-glass
homogenizer. The homogenates were centrifuged (5000 ×
g, 10 min, 4°C) and the TCA was extracted from the super-
natant with 3 × 1.5 ml diethylether. The samples were
kept at -20°C until use. HPLC analysis was performed
exactly as previously described [49]. Protein concentra-
tions were determined by the method of Peterson [50].
Cell culture
Mouse neuroblastoma cells (Neuro 2a) were grown as
previously described in 100 mm Petri dishes containing
10 ml Dulbecco's modified Eagle's medium (DMEM, N.V.
Invitrogen SA, Merelbeke, Belgium), supplemented with
10% fetal calf serum [29]. When the dishes were nearly
confluent (5 – 10 mg of protein/dish), the culture
medium was replaced by 10 ml of saline (145 mM NaCl,
5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 10 mM glucose, 10
mM Hepes-Tris, pH 7.3) containing either 10 μM benfo-
tiamine or 10 μM thiamine. A 10 mM stock solution of
benfotiamine was prepared in a mixture of ethanol (50%)
and water. HCl was added until a homogenous solution
was obtained. After incubation (0 to 4 hours at 37°C), the
cells were centrifuged (2000 × g, 2 min) and the pellet was
suspended in 500 μl TCA (12%). The proteins were sedi-
mented (5000 × g, 3 min) and thiamine derivatives were
determined in the supernatant after extraction of TCA by
diethylether as described above.
Neuro 2a cells were thiamine-depleted as previously
described [8,30]. Briefly the cells were grown in DMEM
medium devoid of thiamine (Invitrogen). The concentra-
tion of fetal calf serum that contains about 14 nM of thia-
mine, was reduced to 5%. The medium was replaced every
2 days and the cells subcultured every 4 days. After 8 days,
either thiamine (1 μM) or benfotiamine (1 μM) were
added and the intracellular thiamine levels were deter-
mined as a function of time (up to 6 h) as described
above.
Statistics
Data were analyzed by multivariate analyses of variance
(MANOVA), followed by ANOVA for follow-up compari-
sons or two-way ANOVA followed by the Bonferroni post-
test.
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